Reviewing Creative Medical Technology (NASDAQ:CELZ) and argenex (NASDAQ:ARGX)

Creative Medical Technology (NASDAQ:CELZ) and argenex (NASDAQ:ARGX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Creative Medical Technology and argenex, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1	0	1	0	2.00
argenex	0	5	17	2	2.88

argenex has a consensus price target of $1,158.61, suggesting a potential upside of 17.24%. Given argenex’s stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Creative Medical Technology.

Volatility and Risk

Creative Medical Technology has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Valuation and Earnings

This table compares Creative Medical Technology and argenex”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10,000.00	662.29	-$5.99 million	($2.07)	-0.49
argenex	$4.25 billion	14.55	$1.29 billion	$26.04	37.95

argenex has higher revenue and earnings than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Creative Medical Technology and argenex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
argenex	32.19%	43.59%	36.66%

Insider and Institutional Ownership

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

argenex beats Creative Medical Technology on 13 of the 15 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.